Compare · HTFL vs WST
HTFL vs WST
Side-by-side comparison of Heartflow Inc. (HTFL) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HTFL and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $25.31B, about 11.8x HTFL ($2.15B).
- Over the past year, HTFL is down 16.6% and WST is up 69.7% - WST leads by 86.3 points.
- Both names hit the wire about 5 times in the past 4 weeks.
- WST has more recent analyst coverage (18 ratings vs 7 for HTFL).
- Company
- Heartflow Inc.
- West Pharmaceutical Services Inc.
- Price
- $24.94-3.86%
- $358.18-1.11%
- Market cap
- $2.15B
- $25.31B
- 1M return
- -22.18%
- +8.72%
- 1Y return
- -16.59%
- +69.72%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 5
- 5
- Recent ratings
- 7
- 18
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest HTFL
- Chief Medical Officer Rogers Campbell exercised 9,219 shares at a strike of $19.00 and sold $237,113 worth of shares (9,219 units at $25.72) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Executive Officer Farquhar John C.M. sold $626,096 worth of shares (22,562 units at $27.75) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 435,373 units (SEC Form 4)
- Director Weldon William C exercised 51,369 shares at a strike of $8.33, increasing direct ownership by 27% to 243,931 units (SEC Form 4)
- New Data at SCCT 2026 Reinforce Heartflow Plaque Analysis as the Standard for AI-Powered Coronary Artery Disease Management
- Chief Executive Officer Farquhar John C.M. sold $1,361,500 worth of shares (38,900 units at $35.00) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 457,935 units (SEC Form 4)
- SEC Form 4 filed by Director Weldon William C
- SEC Form 4 filed by Director Barabe Timothy C
- SEC Form 4 filed by Director Cullivan Julie A
- SEC Form 4 filed by Director Lightcap Jeffrey C
- SEC Form 4 filed by Director Riley Wayne Joseph
Latest WST
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- BNP Paribas Exane initiated coverage on West Pharm with a new price target
- West to Host Second-Quarter 2026 Conference Call
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
- West Pharm upgraded by Barclays with a new price target
- Wolfe Research resumed coverage on West Pharm with a new price target
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits